Multicenter open labeled clinical study in advanced breast cancer patients. a preliminary report

ABSTRACT

Twenty-six patients of advanced breast cancer from nine Egyptian oncology centers received viscum fraxini 2 [VF2]. All patients had exhausted all other lines of treatment [surgical, radiotherapy, chemotherapy and hormonal therapy] and were complaining of various degree of severity of symptoms. Those patients had a life expectancy not less then six months. VF2 was given through subcutaneous injection of 30.000 ngm around or/and intralesional in the site of the primary or recurrent breast lesions. The clinical and laboratory examinations were conducted once weekly. During the treatment trial, no pain controlling or sleeping drugs were used. The end point of assessment was 16 weeks, however, 18 cases continued treatment by viscum for different periods [18-136 weeks]. The total response rate [TRR] at the end of the 16 weeks of treatment was 15/26, while, TRR of cases that continued the treatment more than 16 weeks up to 136 weeks showed an average of 13/18. No TRR difference was noted between pre- and postmenopausal cases